TCG Crossover Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

TCG Crossover Management’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,514,786	Closed	-$45.3M	–	37
2023 Q4	$45.3M	Buy	4,514,786 +1,475,897	+49%	+$6.7M	5.03%	9
2023 Q3	$8.75M	Buy	+3,038,889	New	+$11.1M	1.29%	23

TCG Crossover Management's GRCL Position: Q1 2024 in Review

TCG Crossover Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 4,514,786 shares — an estimated $45.3M sold.

TCG Crossover Management first reported a position in GRCL in Q3 2023 and held it in 2 quarters. The position peaked at $45.3M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

TCG Crossover Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
TCG Crossover Management sold 4,514,786 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $45.3M.
TCG Crossover Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2023 and held it in 2 quarters.
TCG Crossover Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $45.3M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on TCG Crossover Management's 13F filing for Q1 2024, filed 15 May 2024.